LLY

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 1995, for Eli Lilly & Co. The company is a pharmaceutical manufacturer reporting on continuing operations, which include life-sciences products and PCS Health Systems, Inc. (acquired in late 1994). The Medical Devices and Diagnostics (MDD) division is classified as discontinued operations pending divestiture by December 31, 1995.

Key Financial Metrics

Margin Analysis: Cost of sales was 28.4% of sales in Q2 1995 (down from 28.6% in Q2 1994). The effective tax rate for the six months ended June 30, 1995, was 29%, compared to 30.6% in the prior year.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 20% in Q2 1995 and 25% for the six-month period compared to 1994. International sales grew 32% in Q2 and 30% for the six months, driven by volume in emerging markets.
• Product Performance: Prozac sales rose 25% to $513.4 million in Q2. However, U.S. sales of cefaclor dropped 55% to $37.7 million due to the entry of generic competitors in May 1995.
• Expense Increases: Operating expenses rose 28% in Q2 and 27% for the six months. Research and development increased 29% (Q2) and 31% (6 months), driven by late-stage clinical trials (e.g., raloxifene). Marketing and administrative expenses increased 32% (Q2) and 38% (6 months), largely due to the inclusion of PCS Health Systems and global expansion efforts.
• Interest Expense: Interest expense surged to $72.3 million in Q2 1995 from $18.7 million in Q2 1994, reflecting borrowings associated with the PCS acquisition.
• Profitability: Despite strong sales growth, income from continuing operations decreased 3% in Q2 1995 due to higher operating expenses and interest costs. For the six-month period, income from continuing operations increased 10%.

Guidance, Outlook, and Risks

• Outlook: Management expects Prozac sales to continue growing through 1995, though at a lower rate, with total annual sales projected to exceed $2.0 billion. The company anticipates recognizing a net gain upon the completion of the MDD divestiture.
• Legal Contingencies:
  • Product Liability: Ongoing litigation regarding diethylstilbestrol and Prozac. The company has accrued approximately $374 million for gross liabilities, with $147 million in estimated insurance recoverables.
  • Antitrust: The company is a defendant in numerous suits by retail pharmacies alleging antitrust violations and price discrimination. A new suit filed in June 1995 alleges the acquisition of PCS violates antitrust laws; management believes this claim is without merit.
  • Patent Litigation: The company is suing generic manufacturers of cefaclor for patent infringement. A preliminary injunction was denied in August 1995, with patents expiring in July 1996.
• Environmental: The company is a potentially responsible party under Superfund for certain sites and has accrued for estimated cleanup costs.
• Liquidity: Total debt increased to $5.27 billion. The company replaced $500 million of commercial paper with 30-year notes. Management believes cash from operations will be sufficient to fund needs, including debt service and dividends.

Investor Verification Checklist

• Verify the impact of generic cefaclor entry on future U.S. pharmaceutical sales volumes.
• Monitor the outcome of the antitrust litigation regarding the PCS Health Systems acquisition.
• Track the progress of the MDD divestiture and the timing of the expected net gain recognition.
• Assess the sufficiency of the $374 million accrual for product liability claims versus actual litigation costs and insurance recoveries.
• Review the sustainability of R&D spending growth as new compounds enter late-stage clinical trials.